RNA Clinical Trials Articles

1. Learning From Oligos: Delivery & Clinical Strategies For mRNA Therapeutics 3/17/2025

   Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology.

2. Cultivating A Thriving mRNA Ecosystem: Key Initiatives & Future Directions 2/13/2025

   Overall, I felt that the following initiatives/talking points were demonstrative of the types of creativity and symbiosis that we will need much more of in the near and long-term to foster a healthy and fruitful RNA ecosystem. 

3. From Promise To Precision: Defining The Therapeutic Niche for mRNA 1/21/2025

   CureVac CEO Alexander Zehnder shares his thoughts/visions on how mRNA neoantigen vaccines could become even more revolutionary for patient populations in the future. Though it may be early days, this conversation is a great case study for how RNA companies are striving to keep both scientific and commercial market opportunities top of mind from the earliest days of development.

4. The Marriage of Science & Strategy: Identifying mRNA Therapeutics' Value Propositions 1/13/2025

   Though it’s not a question we can answer fully yet, in the first of this two-part article, CureVac CEO Alexander Zehnder starts us down the path of answering a critical question about our RNA therapies: In what ways can and should our mRNA products add value to our patients’ lives?

5. Top 5 mRNA/RNA Developments of 2024 (Part 1) 12/23/2024

   In the past few weeks, I’ve shared two articles outlining several RNA executives’ thoughts on advancements from 2024, as well as the challenges facing us in 2025. But why stop there? Below in the first of this two-part article, I share the first two of my five overarching observations from 2024.

6. "The Ghost Of mRNA's Future": 2025 Outlook From RNA Leaders 12/17/2024

   As the Charles Dickens fans among us already know, there is still one pretty important “ghost” that has yet to be channeled on this “hallowed” page, and that’s the “Ghost of mRNA/RNA Innovations Yet To Come.” (Yes. That’s a thing.) Here, I share several future-facing “visions” from the conversations I had with five RNA leaders.

7. "Ghosts Of mRNA Past & Present": 6 RNA/LNP Execs Revisit 2024 12/10/2024

   But much like Dicken's “A Christmas Carol” with its emphasis on how the past and present inform the future, I was struck by six RNA executive’s appreciation for where we have been and currently are as an industry, and how these moments in time are already informing mRNA/RNA’s bright future.

8. Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 11/26/2024

   EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.

9. Lessons From The Past: How mRNA Can Thrive In The Evolving ATMP Market 11/4/2024

   Fortunately, as multiple presenters during the AGC CDMO Summit explained, there have been a few historical case studies of how the industries preceding us did (or didn’t quite) do the due-diligence they should have to trigger meaningful societal change. Not only do these case studies provide a few tactical pointers for those of us in the mRNA/RNA therapeutics space, I also think they can be particularly instructive in helping us craft/finetune mRNA’s value proposition.

10. A Tale of Two Futures: Financial Trends Shaping The Advanced Therapies Space 10/25/2024

    In the first of this two-part article, I’ll share a few of the commercial nuances informing what the path forward may look like for all of us in the ATMP financial sector.